ANAVEX 2-73 Could Prevent Alzheimer’s Disease in Addition to Modifying and Treating Symptoms

Pre-clinical Study Demonstrates ANAVEX 2-73’s Ability to Preserve Mitochondrial Integrity and Block the Oxidative Stress and Cell Death that Leads to Amyloid-Beta Overproduction and Tau Hyperphosphorylation NEW YORK, NY – February 25, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a research report in the…

Anavex Reports Fiscal First Quarter 2015 Financial Results

NEW YORK, NY – February 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2014. Financial Highlights:…

Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp.

Investigational Alzheimer’s drug candidate ANAVEX 2-73 and drug combination ANAVEX PLUS pharmacodynamic activity to be evaluated using Amarantus’ LymPro Test® in blood samples from Alzheimer’s disease patients Companies to establish scope of biomarker services (initial patient screening for enrollment and ongoing monitoring of drug activity) for clinical trial following ongoing Phase 2a study for ANAVEX…

Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases

NEW YORK, NY – February 9, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform drug for the treatment of other neurodegenerative diseases beyond Alzheimer’s. The data…